marked.bio

Company

Kumquat Biosciences

4 active trials that select patients by a biomarker on marked.bio, across 3 biomarkers.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

cetuximab 1osimertinib 1amivantamab 1

Trials

4 of 4 trials shown

  1. A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

    Not yet recruiting Phase 1 Kumquat Biosciences Started 2026Primary completion 2029-12 NCT07542704

    KQB368

    Malignancy with either a KRAS G12C or KRAS G12S mutation

    KRAS G12CAdvanced Solid Tumors, Colorectal Cancer (CRC), Non-Small Cell Lung Cancer, Uterine Cancer

  2. A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

    Recruiting Phase 1 Kumquat Biosciences Started 2025Primary completion 2029-06 NCT06720987

    KQB365cetuximabKQB198

    …ith KQB198): Histologically confirmed diagnosis of a solid tumor malignancy with either a KRAS G12C or KRAS G12S mutation.

    KRAS G12CKRAS G12C Mutation, KRAS G12S Mutation, Solid Tumor Malignancies, CRC (Colorectal Cancer)

  3. A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies

    Recruiting Phase 1 Kumquat Biosciences Started 2025Primary completion 2026-09 NCT07207707

    KQB548

    Pathologically confirmed, locally advanced or metastatic PDAC, CRC, or NSCLC with a KRAS G12D mutation

    KRAS G12DSolid Tumor Malignancies

  4. A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

    Active, not recruiting Phase 1 Kumquat Biosciences Started 2024Primary completion 2026-12 NCT06507306

    KQB198osimertinib FDA EUamivantamab FDA EU

    … arms) and Part 2 Cohort A and Cohort B: Histologically confirmed diagnosis of NSCLC with activating EGFR mutation and progression on osimertinib

    EGFR exon 19 deletion / L858REGFR exon 20 insertionSolid Tumor, Adult